News

Interview with Dr. Anneke Hesseling – Part Three

This is part three of our interview with Dr. Hesseling. Click here to view part one. Click here to view part two.

Dr. Anneke Hesseling is the Director of the Paediatric TB Research Program at the Desmond Tutu TB Centre at Stellenbosch University in Cape Town, South Africa. She has South African and US training in Medicine and Epidemiology and is the PI and co-PI on several large research projects relates to the epidemiology, transmission and diagnosis of tuberculosis in children, with special emphasis on the interaction between pediatric TB and HIV and the immunologic diagnosis of TB infection and disease. Dr. Hesseling has a special research interest in the epidemiologic and immunologic interaction between BCG and HIV in children and is the chairperson of the IUATLD BCG Working Group.

An interview with Dr. Hesseling from the 41st Union World Conference on Lung Health in Berlin can be found on the Science Speaks blog here.

More News
17 Sep 2019
Earlier this month, the NIH announced two new Funding Opportunity Annoucnements (FOAs) on the topic of Myeloid-Derived Suppressor Cells (MDSC) as potential therapeutic targets in TB/HIV co-infected patients. The purpose of these FOAs is to invite applications for support of innovative clinical,...
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...